Development
Cullinan Therapeutics, Inc.
CGEM
$8.08
$0.141.76%
NASDAQ
| 12/31/2023 | 09/30/2023 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -3.14% | 7.52% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 1.52% | 19.14% | |||
| Operating Income | -1.52% | -19.14% | |||
| Income Before Tax | -1.28% | -21.63% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 34.76% | -21.63% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 39.25% | -21.63% | |||
| EBIT | -1.52% | -19.14% | |||
| EBITDA | -1.53% | -19.19% | |||
| EPS Basic | 39.34% | -13.72% | |||
| Normalized Basic EPS | 4.96% | -12.44% | |||
| EPS Diluted | 39.34% | -11.82% | |||
| Normalized Diluted EPS | 4.96% | -12.44% | |||
| Average Basic Shares Outstanding | 0.14% | 6.96% | |||
| Average Diluted Shares Outstanding | 0.14% | 6.96% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||